北京地区2008~2014年膦甲酸钠不良反应分析

胡扬,刘一,刘水,张波,梅丹,朱兰

中国药学杂志 ›› 2015, Vol. 50 ›› Issue (18) : 1634-1638.

PDF(840 KB)
PDF(840 KB)
中国药学杂志 ›› 2015, Vol. 50 ›› Issue (18) : 1634-1638. DOI: 10.11669/cpj.2015.18.013
药物与临床

北京地区2008~2014年膦甲酸钠不良反应分析

  • 胡扬 1,刘一2,刘水3,张波1,梅丹1*,朱兰4
作者信息 +

Analysis of Foscarnet-induced Adverse Drug Reaction in Beijing Area from 2008 to 2014

  • HU Yang1,LIU Yi2, LIU Shui3, WANG Lan1, ZHANG Bo1,MEI Dan1*, ZHU Lan4
Author information +
文章历史 +

摘要

目的 统计分析北京地区近6年来膦甲酸钠的不良反应报告,为膦甲酸钠的安全合理应用提供依据。方法 收集2008年3月~2014年12月北京市药品不良反应监测中心数据库中膦甲酸钠不良反应报告,并对152例不良反应统计分析ADR报告类型、ADR发生时间、患者年龄、性别和民族分布、严重不良反应、过敏史、给药途径、剂型、用量、用药原因、患者既往ADR史、ADR累及器官/系统及表现、ADR关联性评价结果、ADR处理及预后。结果 膦甲酸钠致ADR在31~60岁发生率较高,55.3%的ADR发生于用药后24 h内,临床表现复杂多样,涉及机体多个器官或系统,主要和严重的不良反应为肾损害及癫痫发作。结论 膦甲酸钠的安全性是临床应关注的问题,应在合理使用的基础上,监测并及时处理其不良反应。

Abstract

OBJECTIVE To analyze the reports of foscarnet-induced adverse drug reaction (ADR) in Beijing area in the recent 6 years, and to provide reference for rational use of foscarnet.METHODS One hundred and fifty-two reports of ADR from March 2008 to December 2014 induced by foscarnet received by Beijing drug adverse reaction monitoring center were collected. The type and time of ADR,the age of patient, the gender and nation of patient, serious adverse reactions, allergy history, administration, dosage, preparation, the indication,ADR history,ADR involved organ and system ,the causal relationship, treatments and prognosis were retrospectively analyzed.RESULTS The ADR induced by foscarnet were more often occurred in patients aged from 31 to 60, with 55.3% appearing within 24 h after drug use. The clinical presentation was complex and diverse, which involved different systems and organs, predominantly the lesion of renal function and epilepticseizures.CONCLUSION Safe to use with foscarnet is worth paying attention by clinicans, who should detect and deal with ADR of foscarnet in time on basis of rational use.

关键词

膦甲酸钠 / 药品不良反应 / 分析

Key words

foscarnet / adverse drug reaction / analysis

引用本文

导出引用
胡扬,刘一,刘水,张波,梅丹,朱兰. 北京地区2008~2014年膦甲酸钠不良反应分析[J]. 中国药学杂志, 2015, 50(18): 1634-1638 https://doi.org/10.11669/cpj.2015.18.013
HU Yang,LIU Yi, LIU Shui, WANG Lan, ZHANG Bo,MEI Dan, ZHU Lan. Analysis of Foscarnet-induced Adverse Drug Reaction in Beijing Area from 2008 to 2014[J]. Chinese Pharmaceutical Journal, 2015, 50(18): 1634-1638 https://doi.org/10.11669/cpj.2015.18.013
中图分类号: R969.3   

参考文献

[1] OBERG B. Antiviral effects of phosphonoformate(PFA, foscarnet sodium)[J]. Pharm Ther, 1989,40(2):213-285.
[2] SAFRIN S, CRUMPACKER C, CHATIS P, et al. A controlled trial comparing foscarnet with vidrabine for acyclovir-resistant mucocutaneous herpes-simplex in the acquired-immunodeficiency-syndrome[J]. N Engl J Med,1991,325(8):551-555.
[3] FDA. Drugs@FDA [EB/OL]. (2014-1-13)[2012-10-2]. http://www. accessdata. fda. gov/drugsatfda_docs/label/2012/020068s018lbl. pdf.
[4] WANG Y. Clinical observation ofdifferent doses of foscarnet for herpes zoster [J]. Strait Pharm J(海峡药学),2010,22(5):138-139.
[5] DERAY G,MARTINEZ F, KATIAMA C, et al. Foscarnet nephrotoxicity-mechanism, incidence and prevention [J]. Am J Nephrol,1989,9(4):316-321.
[6] MAURICE L, DAUDON M, KATLAMA C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet[J]. Am J Kidney Dis, 1998,32(3):392-400.
[7] NYBERG G,SYALANDER C,BLOHME I, et al. Tubulointerstitial nephritis caused by the antiviral agent foscarnet [J]. Transpl Int, 1989, 2(4):223-227.
[8] IZZEDINE H,LAUNAY V, DERAY G. Antiviral drug-induced nephrotoxicity[J]. Am J Kidney Dis, 2005, 45(5) : 804-817.
[9] WAGSTAFF A J,BRYSON H. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections[J]. Drugs,1994,48(8):199.
[10] ZHANG Z W,CAI S Q,YE J. The antiviral research progress of foscarnet [J]. Mod Med Health(现代医药卫生), 2000,16(5):384-386.
[11] LI J P. The research status and applied use for foscarnet[J]. Tianjin Pharm(天津医学), 2002,14(6):12-13.
[12] WANG P,PENG H,LOU F D, et al. Hypocalcemia and hypokalemia due tofoscarnet[J]. Chin J Hosp Pharm(中国医院药学杂志), 2001, 21(1): 62.
[13] ZHANG T,ZHU K E. Epilepsy due to foscarne after hemopoietic stem cell tramplantation[J]. J Clinical Hematology(临床血液学杂志),2006, 19(3):178-179.
[14] SHENG J L,SHEN J L,DONG W. Epilepsy due to foscarnet[J]. Adv Drug React J(药物不良反应杂志), 2000, 2(4): 220.
[15] FANHARVARD P,SANCHORAWALA V, OH J, et al. Concurrentuse of foscarnet and ciprofloxacinmay increase the propensity for seizures[J]. Ann Pharmacother, 1994, 28(7-8): 869-872.
[16] WHARTON J R, LAUGHLIN C. Toxic epidermal necrolysis occurring as a consequence of treatment with foscarnet[J]. Cutis, 1999, 63(6):333-335.
[17] LAWRENCE A. Handbook on Injectable Drugs[M]. 16th Edition. Maryland:American Society of Health-System Pharmacists,2011:719.

基金

国家临床重点专科建设项目
PDF(840 KB)

Accesses

Citation

Detail

段落导航
相关文章

/